Rhythm Pharmaceuticals
RYTM
143 hedge funds and large institutions have $1.56B invested in Rhythm Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 12 closing their positions.
732% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $1.32M
225% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 12
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
43% more capital invested
Capital invested by funds: $1.09B → $1.56B (+$470M)
23% more funds holding
Funds holding: 116 → 143 (+27)
23% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 39
3.29% more ownership
Funds ownership: 116.45% → 119.74% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$46.5M |
| 2 |
O
OrbiMed
New York
|
+$13.1M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.96M |
| 4 |
PA
Perceptive Advisors
New York
|
+$8.53M |
| 5 |
Morgan Stanley
New York
|
+$7.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$34.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$20.2M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$13.9M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.7M |
| 5 |
Walleye Capital
New York
|
-$6.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EFM
151
E Fund Management
Guangzhou,
China
| – | -$230K | -13,948 | Closed |
|
|
VF
152
Virtu Financial
New York
| – | -$217K | -13,188 | Closed |
|
|
HP
153
Harbourvest Partners
Boston,
Massachusetts
| – | -$93K | -5,639 | Closed |
|
154
Russell Investments Group
London,
United Kingdom
| – | -$18.1K | -1,100 | Closed |
|
|
BHWM
155
Beaird Harris Wealth Management
Dallas,
Texas
| – | -$809 | -49 | Closed |
|
|
C
156
Covestor
London,
United Kingdom
| – | +$157 | +7 | New |
|
RYTM Hedge Fund Activity: Q3 2023 in Review
143 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2023, worth a combined $1.56B — up 43% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new RYTM positions and 12 closed out — a net gain of 27 holders — while 48 added to existing stakes and 39 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $46.5M. The largest seller was Federated Hermes, cutting an estimated $34.7M.
- 143 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2023, up from 116 in Q2 2023.
- Funds reported $1.56B of Rhythm Pharmaceuticals stock for Q3 2023, up 43% quarter-over-quarter.
- 39 funds opened new Rhythm Pharmaceuticals positions in Q3 2023 and 12 closed out, a net change of +27 holders.
- The largest Rhythm Pharmaceuticals buyer in Q3 2023 was Commodore Capital, an estimated $46.5M added.
- The largest Rhythm Pharmaceuticals seller in Q3 2023 was Federated Hermes, an estimated $34.7M sold.
Based on aggregated 13F filings for Q3 2023.